Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03581630
Other study ID # 3-2017-0097
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 29, 2017
Est. completion date July 22, 2018

Study information

Verified date August 2018
Source Gangnam Severance Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Obesity among breast cancer survivors is known to be associated with recurrence and other co-morbidities. However, there have been no studies on weight reduction program combining diet and anti-obesity drug for obese breast cancer survivors. The purpose of this randomized clinical trial is to examine the effects of Mediterranean Diet and naltrexone/bupropion treatment on inflammation and metabolic risk factors in overweight or obese breast cancer patients after breast cancer treatment.


Recruitment information / eligibility

Status Completed
Enrollment 72
Est. completion date July 22, 2018
Est. primary completion date July 22, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 20 Years to 65 Years
Eligibility Inclusion Criteria:

- Female, 20 to 65 years of age

- Diagnosed with breast cancer stage ?-?, and have completed cancer treatment including breast surgery and/or adjuvant chemotherapy, radiotherapy, hormonal therapy

- BMI =25 kg/m2, or BMI =23 kg/m2 with one or more of the metabolic risk factors (waist circumference =80 cm, fasting glucose =100 mg/dL, BP =130/85 mmHg, HDL-cholesterol <50 mg/dL or controlled diabetes, hypertension, dyslipidemia with medications)

- If woman of child bearing potential, agree to use effective contraception throughout the study period and 30 days after discontinuation of study drug

- Able to speak and read Korean

- Able to comply with all required study procedures and schedule

- Willing and able to give written informed consent

Exclusion Criteria:

- Participants with cancer recurrence or metastasis

- Participants with uncontrolled hypertension (systolic blood pressure (SBP) >180 mmHg, or diastolic blood pressure (DBP) >120 mmHg)

- Participants with hepatic disease (aspartate aminotransferase (AST)/alanine aminotransferase (ALT) >3 x institutional upper limit of normal) or renal disease (serum creatinine >2.0 mg/dL)

- Participants with significant cardiovascular disease or stroke

- Participants with history of seizures

- Participants with serious psychiatric illness, including bipolar disorder, schizophrenia, or other psychosis, bulimia, anorexia nervosa, or suicidal ideation

- Participants who are taking medications such as monoamine oxidase (MAO) inhibitors, opioid-containing medications, other naltrexone or bupropion containing medications, and Tamoxifen

- Current smokers or use of nicotine replacement products in the previous 6 months

- Pregnant or breast-feeding women

- Any condition which in the opinion of the investigator makes the subject unsuitable for inclusion in this study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
naltrexone/bupropion
Naltrexone hydrochloride (HCl) 8 mg/Bupropion hydrochloride (HCl) 90 mg extended release (ER) combination tablets, orally, one tablet, in the morning, daily, for 1 week, followed by Naltrexone HCl 8 mg/Bupropion HCl 90 mg ER combination tablets, orally, one tablet in the morning and one in the evening, daily, for 7 weeks.
Behavioral:
Mediterranean Diet
Diet instruction and menu samples from the dietitian on following the Mediterranean Diet.

Locations

Country Name City State
Korea, Republic of GangnamSeverance Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Gangnam Severance Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in body weight body weight (kg) baseline, 8 weeks
Primary Change in fat mass fat mass (kg) measured by bioelectrical impedance analyzer baseline, 8 weeks
Primary Change in muscle mass muscle mass (kg) measured by bioelectrical impedance analyzer baseline, 8 weeks
Primary Change in fasting glucose fasting glucose (mg/dL) baseline, 8 weeks
Primary Change in insulin insulin (mcIU/mL) baseline, 8 weeks
Primary Change in triglyceride triglyceride (mg/dL) baseline, 8 weeks
Primary Change in high-density lipoprotein cholesterol (HDL-cholesterol) HDL-cholesterol (mg/dL) baseline, 8 weeks
Primary Change in leukocyte count leukocyte count (/µL) baseline, 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Recruiting NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2